ClinicalTrials.gg
CompletedNCT04056754Updated Aug 14, 2019

Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer

A Phase 3 interventional study of Abiraterone Acetate and Placebo in Metastatic Castration Resistant Prostate Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 16 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-14.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years after the study started (first participant enrolled Jul 2014, registered Aug 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
14th of 98
268 · median 56
Started
2014
with 9 others
Phase 3
11 of 98
2 open now
Registered
70th of 98
by date

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 14th largest by enrollment, is one of 10 that started in 2014, is one of 11 in phase 3, and was the 70th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Abiraterone acetate is an orally effective CYP17 inhibitor, which is metabolized into abiraterone in the body, and its inhibitory activity against CYP17 is 10-30 times that of ketoconazole. Clinical studies have shown that abiraterone acetate can significantly reduce the level of prostate specific antigen (PSA) in PCa patients, and help to reduce tumors, extending the lifespan of patients with advanced PCa for several years, and the toxicity is acceptable.

03

Conditions studied

  • Metastatic Castration Resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- 1.18 years and older, (ECOG) performance status of 0 to 1, ≥ 6 months.

2. Prostate cancer. 3. Serum testosterone \<50 ng/dL (or 1.7 nmol/L). 4. Prostate cancer progression or lesion . 5. Restriction of antiandrogen therapy. 6. Restriction of Radiation therapy. 7. The treatment period of ketoconazole for prostate cancer was not exceed 7 days.

8. Has not used opioid analgesics and azole drugs within 4 weeks before the first dose.

9. Question 3 of the Concise Pain Questionnaire (BPI-SF) scored from 0-3 points.

10. Adequate laboratory indicators. 11. Must be able to swallow tablets. 12. No pregnant or breastfeeding women, and a negative pregnancy test. 13. Understood and signed an form.

Exclusion criteria

Exclusion Criteria:

  1. Prostate pathology results are neuroendocrine prostate cancer.
  2. Has received cytotoxic chemotherapy or biological therapy for castration resistant prostate cancer.
  3. Has to the use of prednisone.
  4. A chronic disease that exceeds the prednisone dose in the study.
  5. Uncontrolled high blood pressure.
  6. Active or symptomatic viral hepatitis or other chronic liver disease.
  7. Visceral metastasis or .
  8. Pituitary or adrenal dysfunction.
  9. Active diseases require the use of hormone therapy.
  10. heart disease.
  11. Participated in other clinical trials within 4 weeks.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
268 participants (actual)

Study arms

  • Experimental
    Abiraterone acetate group

    Subjects in this group administered 4 tablets abiraterone acetate once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.

    Drug: Abiraterone Acetate · Drug: Prednisone

  • Placebo comparator
    Placebo group

    Subjects in this group administered 4 tablets abiraterone acetate blank analog tablet once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.

    Drug: Placebo · Drug: Prednisone

Interventions

  • Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.

  • DrugPlacebo

    Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.

  • Subjects administered 5mg prednisone twice daily in 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Time to PSA progression (TTPP)

    The time interval between the administration of the drug and the progression of serum prostate specific antigen (PSA).

    Time frame: Baseline up to 24 months

Secondary outcomes

  1. Prostate specific antigen remission time

    It was ≥50% lower than the baseline, and was confirmed as remission after re-testing after ≥4 weeks.

    Time frame: Baseline up to 24 months

  2. Objective Response Rate (ORR)

    The percentage of participants with a best overall response defined as complete response (CR) or partial response (PR).

    Time frame: Baseline up to 24 months

  3. Eastern Cooperative Oncology Group (ECOG)

    The ECOG scoring standard is an indicator of the general health status and tolerance to treatment from the patient's physical strength. ECOG physical status score standard from 0 to 5. Starting with the dose until the score increases from the baseline.

    Time frame: Baseline up to 24 months

  4. Overall Survival (OS)

    Time from date of randomization to date of death due to any cause.

    Time frame: Baseline up to 24 months

  5. To pain progression time

    Time from the start of medication to the progression of pain.

    Time frame: Baseline up to 24 months

  6. Quality of life assessment scale (FACT-P)

    Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P) total score, Functional Assessment of Cancer Therapy- General (FACT-G) total score, trial outcome index, functional well-being, physical well-being, prostate cancer subscale, and Functional Assessment of Cancer Therapy (FACT) Advanced Prostate Symptom Index-6 (FAPSI-6).

    Time frame: Baseline up to 24 months

  7. Prostate specific antigen remission rate

    The remission rate was defined as the proportion of remissions to the total number of people.

    Time frame: Baseline up to 24 months

07

Study locations

16 sites
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100000, China
  • Peking University First Hospital
    Beijing, Beijing Municipality 100000, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing Municipality 400000, China
  • Sun-Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510000, China
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530000, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Guangzhou Military Region Wuhan General Hospital
    Wuhan, Hubei 430000, China
  • TongJi medical college of HuaZhong University of Science & Technology Affiliated TongJi Hospital
    Wuhan, Hubei 430000, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210000, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250000, China
  • Fudan University Medical College Affiliated Huadong Hospital
    Shanghai, Shanghai Municipality 200000, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200000, China
  • RenJi Hospital of Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200000, China
  • West China Hospital,Sichuan University
    Chengdu, Sichuan 610000, China
  • The Second Affiliated Hospital of Zhenjiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Mar 2018, 43 months.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 43 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2019
First posted
Aug 14, 2019
StartActual
Jul 16, 2014
Primary completionActual
Mar 14, 2018
CompletionActual
Jul 16, 2019
Last update
Aug 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04056754
Responsible party
Sponsor
First posted
Aug 14, 2019
Start date
Jul 16, 2014
Primary completion
Mar 14, 2018
Completion
Jul 16, 2019
Last update
Aug 14, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion